VX 708
Alternative Names: VX-708Latest Information Update: 22 May 2023
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute pain
Most Recent Events
- 14 Apr 2023 Vertex Pharmaceuticals completes a phase I trial for Acute Pain in United Kingdom (PO) (NCT05347394)
- 07 Mar 2023 Vertex Pharmaceuticals completes a phase I trial for Acute pain (Combination therapy, In volunteers) in March 2023 (IV) (NCT05518734)
- 17 Sep 2022 Phase-I clinical trials in Acute pain (In volunteers, Combination therapy) in USA (IV) (NCT05518734)